BrickBio, Inc.
John Boyce is a seasoned entrepreneur and executive in the life sciences sector, currently serving as the Managing Director and Co-Founder of TigerGene LLC, a venture capital fund focused on early-stage life science technologies. Boyce co-founded and leads BrickBio and NanoMosaic, companies that specialize in innovative therapeutic conjugation and protein detection technologies, respectively. Previously, Boyce held leadership roles at Exosome Diagnostics, GnuBIO, and Delphi Bio Consulting, where significant value was created for investors. Additionally, Boyce contributes to academia as a Harvard Fellow, teaching innovation and entrepreneurship. Notable achievements include successful exits that yielded high returns on investment and the founding of the Consumer Genetics Conference, which highlighted advancements in direct-to-consumer genetic testing.
This person is not in any teams
BrickBio, Inc.
BrickBio is a developer of a bioconjugation platform intended for research of site-specific modification of proteins. The company's platform can optimize any conjugate with the selective modification of a number of distinct websites on a single protein through its prokaryotic and eukaryotic expression programs, thereby providing hospitalswith amino acid coupled therapeutics to improve protein characteristics.